SPY402.13+0.41 0.10%
DIA324.27+2.04 0.63%
IXIC11,736.57-68.43 -0.58%

BRIEF-FDA Announces Vaccines And Related Biological Products Advisory Committee Review Of Novavax' Covid-19 Vaccine

reuters.com · 04/29/2022 11:10
BRIEF-FDA Announces Vaccines And Related Biological Products Advisory Committee Review Of Novavax' Covid-19 Vaccine

- Novavax Inc NVAX:

  • FDA ANNOUNCES VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE REVIEW OF NOVAVAX' COVID-19 VACCINE

  • NOVAVAX INC - NVX-COV2373 WOULD BE FIRST PROTEIN-BASED COVID-19 VACCINE TO BE REVIEWED BY VRBPAC IN U.S.

  • NOVAVAX INC - FDA VRBPAC TO REVIEW NVX-COV2373 COVID-19 VACCINE (RECOMBINANT, ADJUVANTED) FOR ACTIVE IMMUNIZATION AGAINST SARS-COV-2 AT MEETING ON JUNE 7, 2022

  • NOVAVAX INC - LOOK FORWARD TO A PRODUCTIVE VRBPAC MEETING AND WILL CONTINUE TO WORK WITH FDA THROUGHOUT REVIEW PROCESS

Source text for Eikon: ID:nPn4LCWk8a

Further company coverage: NVAX


((Reuters.Briefs@thomsonreuters.com;))